Precision-medicine IPO deserves Groupon discount

Groupon

31/05/2024 16:18

(The author is a Reuters Breakingviews columnist.  The opinions
expressed are his own.)
    By Robert Cyran
       NEW YORK, May 31 (Reuters Breakingviews) - Tempus helps
tailor treatments with its library of DNA and other tests. In a
market giddy about AI, it could be worth $6 bln. One hitch is
that founder Eric Lefkofsky, who started the online coupon
provider, will keep control. The marginal value of its data is
also shrinking.
    
    Full view will be published shortly.
    Follow @rob_cyran on X
         
    CONTEXT NEWS 
    Tempus AI, which collects and analyzes molecular and
clinical data from patients, disclosed its plans for an initial
public offering on May 20.
    The company generated $532 million of revenue in 2023, a 66%
increase from the previous year. Its annual net loss narrowed to
$214 million from $290 million.

 (Editing by Jeffrey Goldfarb and Pranav Kiran)
 ((For previous columns by the author, Reuters customers can
click on  CYRAN/ 
robert.cyran@thomsonreuters.com; Reuters Messaging:
robert.cyran.thomsonreuters.com@reuters.net))